• ChemoMetec raised its 2026/27 revenue forecast to DKK 570-605 million from DKK 560-590 million.
• EBITDA guidance increased to DKK 335-360 million from DKK 330-345 million.
• The upgrade reflected stronger-than-expected instrument demand, particularly for the NC-203, alongside lower-than-expected costs.
• First-quarter revenue rose 28% to DKK 160 million, compared with DKK 124.6 million a year earlier.
• Quarterly EBITDA reached DKK 100.3 million, with a 63% margin versus 55% a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ChemoMetec A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030421OMX_____CNEWS_EN_GNW1001301454_en) on November 03, 2026, and is solely responsible for the information contained therein.